- Home
- KRON vs AVTE Comparison
KRON vs AVTE Comparison
Compare KRON & AVTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRON
- AVTE
- Stock Information
- Founded
- KRON 2017
- AVTE 2018
- Country
- KRON United States
- AVTE United States
- Employees
- KRON N/A
- AVTE N/A
- Industry
- KRON Medicinal Chemicals and Botanical Products
- AVTE Biotechnology: Pharmaceutical Preparations
- Sector
- KRON Health Care
- AVTE Health Care
- Exchange
- KRON Nasdaq
- AVTE Nasdaq
- Market Cap
- KRON 61.5M
- AVTE 72.5M
- IPO Year
- KRON 2020
- AVTE 2021
- Fundamental
- Price
- KRON $0.83
- AVTE $2.53
- Analyst Decision
- KRON Buy
- AVTE Hold
- Analyst Count
- KRON 3
- AVTE 7
- Target Price
- KRON $1.63
- AVTE $11.75
- AVG Volume (30 Days)
- KRON 165.9K
- AVTE 66.1K
- Earning Date
- KRON 03-18-2025
- AVTE 03-27-2025
- Dividend Yield
- KRON N/A
- AVTE N/A
- EPS Growth
- KRON N/A
- AVTE N/A
- EPS
- KRON N/A
- AVTE N/A
- Revenue
- KRON $9,848,000.00
- AVTE N/A
- Revenue This Year
- KRON N/A
- AVTE N/A
- Revenue Next Year
- KRON N/A
- AVTE N/A
- P/E Ratio
- KRON N/A
- AVTE N/A
- Revenue Growth
- KRON 56.62
- AVTE N/A
- 52 Week Low
- KRON $0.69
- AVTE $1.25
- 52 Week High
- KRON $1.60
- AVTE $32.42
- Technical
- Relative Strength Index (RSI)
- KRON 27.47
- AVTE 55.27
- Support Level
- KRON $0.82
- AVTE $2.44
- Resistance Level
- KRON $0.95
- AVTE $2.56
- Average True Range (ATR)
- KRON 0.06
- AVTE 0.09
- MACD
- KRON -0.01
- AVTE 0.01
- Stochastic Oscillator
- KRON 3.12
- AVTE 82.86
About KRON Kronos Bio Inc.
Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine plan by targeting dysregulated transcription. The company operates in one business segment, the development of biopharmaceutical products.
About AVTE Aerovate Therapeutics Inc.
Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. The initial focus of the company is on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension.